$CVRX
CVRx, Inc.

2024 Q4 Form 10-Q Financial Statement

#000155837024014078 Filed on November 01, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $13.37M
YoY Change 27.23%
Cost Of Revenue $2.248M
YoY Change 32.94%
Gross Profit $11.13M
YoY Change 26.13%
Gross Profit Margin 83.19%
Selling, General & Admin $21.63M
YoY Change 38.21%
% of Gross Profit 194.44%
Research & Development $2.504M
YoY Change -7.12%
% of Gross Profit 22.51%
Depreciation & Amortization $169.0K
YoY Change 23.36%
% of Gross Profit 1.52%
Operating Expenses $24.14M
YoY Change 31.55%
Operating Profit -$13.01M
YoY Change 36.56%
Interest Expense -$958.0K
YoY Change -291.98%
% of Operating Profit
Other Income/Expense, Net $917.0K
YoY Change -13.16%
Pretax Income -$13.05M
YoY Change 45.49%
Income Tax $47.00K
% Of Pretax Income
Net Earnings -$13.10M
YoY Change 45.37%
Net Earnings / Revenue -97.95%
Basic Earnings Per Share -$0.57
Diluted Earnings Per Share -$0.57
COMMON SHARES
Basic Shares Outstanding 24.26M 21.79M
Diluted Shares Outstanding 22.78M

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $100.2M
YoY Change 20.68%
Cash & Equivalents $100.2M
Short-Term Investments
Other Short-Term Assets $2.786M
YoY Change -15.58%
Inventory $11.89M
Prepaid Expenses
Receivables $9.033M
Other Receivables $0.00
Total Short-Term Assets $123.9M
YoY Change 19.57%
LONG-TERM ASSETS
Property, Plant & Equipment $2.631M
YoY Change 52.7%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $26.00K
YoY Change 0.0%
Total Long-Term Assets $3.801M
YoY Change 35.41%
TOTAL ASSETS
Total Short-Term Assets $123.9M
Total Long-Term Assets $3.801M
Total Assets $127.7M
YoY Change 19.99%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.276M
YoY Change 189.14%
Accrued Expenses $7.671M
YoY Change 22.27%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $10.95M
YoY Change 47.79%
LONG-TERM LIABILITIES
Long-Term Debt $49.21M
YoY Change 244.3%
Other Long-Term Liabilities $1.378M
YoY Change 43.54%
Total Long-Term Liabilities $50.59M
YoY Change 231.66%
TOTAL LIABILITIES
Total Short-Term Liabilities $10.95M
Total Long-Term Liabilities $50.59M
Total Liabilities $62.49M
YoY Change 165.05%
SHAREHOLDERS EQUITY
Retained Earnings -$526.7M
YoY Change 12.49%
Common Stock $592.1M
YoY Change 7.41%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $65.18M
YoY Change
Total Liabilities & Shareholders Equity $127.7M
YoY Change 19.99%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$13.10M
YoY Change 45.37%
Depreciation, Depletion And Amortization $169.0K
YoY Change 23.36%
Cash From Operating Activities -$10.41M
YoY Change 28.2%
INVESTING ACTIVITIES
Capital Expenditures $37.00K
YoY Change -7.5%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$37.00K
YoY Change -7.5%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 40.20M
YoY Change 11067.22%
NET CHANGE
Cash From Operating Activities -10.41M
Cash From Investing Activities -37.00K
Cash From Financing Activities 40.20M
Net Change In Cash 29.76M
YoY Change -481.47%
FREE CASH FLOW
Cash From Operating Activities -$10.41M
Capital Expenditures $37.00K
Free Cash Flow -$10.45M
YoY Change 28.03%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.57
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.43
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.25
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.55
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
22783337
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
20801350
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21884588
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
20730024
CY2024Q2 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrent
CY2023Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrent
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
22783337
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
20801350
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21884588
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20730024
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.57
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.43
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.25
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.55
dei Entity Central Index Key
EntityCentralIndexKey
0001235912
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
24203658
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
20879199
CY2024Q2 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrent
CY2023Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrent
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-40545
dei Entity Registrant Name
EntityRegistrantName
CVRx, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
41-1983744
dei Entity Address Address Line1
EntityAddressAddressLine1
9201 West Broadway Avenue
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 650
dei Entity Address City Or Town
EntityAddressCityOrTown
Minneapolis
dei Entity Address State Or Province
EntityAddressStateOrProvince
MN
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
55445
dei City Area Code
CityAreaCode
763
dei Local Phone Number
LocalPhoneNumber
416-2840
dei Security12b Title
Security12bTitle
Common stock,
dei Trading Symbol
TradingSymbol
CVRX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
24263663
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
100161000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
90569000
CY2024Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
522000
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
508000
CY2024Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
9033000
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
7551000
CY2024Q3 us-gaap Inventory Net
InventoryNet
11892000
CY2023Q4 us-gaap Inventory Net
InventoryNet
10983000
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2786000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2987000
CY2024Q3 us-gaap Assets Current
AssetsCurrent
123872000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
112090000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2631000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1763000
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1144000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1349000
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
26000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
27000
CY2024Q3 us-gaap Assets
Assets
127673000
CY2023Q4 us-gaap Assets
Assets
115229000
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
3276000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1884000
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7671000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5980000
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
10947000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
7864000
CY2024Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
49214000
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
29222000
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
951000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1160000
CY2024Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1378000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1036000
CY2024Q3 us-gaap Liabilities
Liabilities
62490000
CY2023Q4 us-gaap Liabilities
Liabilities
39282000
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
24203658
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
20879199
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
242000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
209000
CY2024Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
591844000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
553326000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-526695000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-477381000
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-208000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-207000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
65183000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
75947000
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
127673000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
115229000
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
13373000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
10511000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
35950000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
27990000
CY2024Q3 us-gaap Cost Of Revenue
CostOfRevenue
2248000
CY2023Q3 us-gaap Cost Of Revenue
CostOfRevenue
1691000
us-gaap Cost Of Revenue
CostOfRevenue
5763000
us-gaap Cost Of Revenue
CostOfRevenue
4536000
CY2024Q3 us-gaap Gross Profit
GrossProfit
11125000
CY2023Q3 us-gaap Gross Profit
GrossProfit
8820000
us-gaap Gross Profit
GrossProfit
30187000
us-gaap Gross Profit
GrossProfit
23454000
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2504000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2696000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8326000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9392000
CY2024Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
21632000
CY2023Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
15652000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
71077000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
47504000
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
24136000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
18348000
us-gaap Operating Expenses
OperatingExpenses
79403000
us-gaap Operating Expenses
OperatingExpenses
56896000
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-13011000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-9528000
us-gaap Operating Income Loss
OperatingIncomeLoss
-49216000
us-gaap Operating Income Loss
OperatingIncomeLoss
-33442000
CY2024Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
958000
CY2023Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
499000
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
2877000
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
1220000
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
917000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1056000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2905000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2734000
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-13052000
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-8971000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-49188000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-31928000
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
47000
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
40000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
126000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
108000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-13099000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-9011000
us-gaap Net Income Loss
NetIncomeLoss
-49314000
us-gaap Net Income Loss
NetIncomeLoss
-32036000
CY2024Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
2000
CY2023Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-21000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-1000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-1000
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-13097000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9032000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-49315000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-32037000
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.57
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.57
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.43
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.43
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.25
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.55
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
22783337
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
22783337
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20801350
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
20801350
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21884588
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20730024
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
55248000
CY2024Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
728000
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2680000
CY2024Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
19624000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-13099000
CY2024Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
2000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
65183000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
89964000
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
363000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1532000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-9011000
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-21000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
82827000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
75947000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1610000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
406000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
16365000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
20170000
us-gaap Net Income Loss
NetIncomeLoss
-49314000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
65183000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
109180000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
519000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
452000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4713000
us-gaap Net Income Loss
NetIncomeLoss
-32036000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
82827000
us-gaap Profit Loss
ProfitLoss
-49314000
us-gaap Profit Loss
ProfitLoss
-32036000
us-gaap Share Based Compensation
ShareBasedCompensation
16365000
us-gaap Share Based Compensation
ShareBasedCompensation
4713000
us-gaap Depreciation
Depreciation
441000
us-gaap Depreciation
Depreciation
393000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-4000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
142000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
114000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1482000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
868000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
909000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
3930000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-242000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-902000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1392000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-586000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1987000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
112000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-31136000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-31182000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1309000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
422000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1309000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-422000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1610000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
519000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
406000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
452000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
20170000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
us-gaap Proceeds From Long Term Lines Of Credit
ProceedsFromLongTermLinesOfCredit
20000000
us-gaap Proceeds From Long Term Lines Of Credit
ProceedsFromLongTermLinesOfCredit
7500000
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
150000
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
67000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
42036000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
8404000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-1000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
9592000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-23201000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
90569000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
106194000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
100161000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
82993000
us-gaap Interest Paid Net
InterestPaidNet
2456000
us-gaap Interest Paid Net
InterestPaidNet
979000
us-gaap Income Taxes Paid
IncomeTaxesPaid
0
us-gaap Income Taxes Paid
IncomeTaxesPaid
4000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Use of estimates</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and the accompanying notes. Actual results could differ from those estimates.</p>
CY2024Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
6531000
CY2023Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
4714000
CY2024Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
280000
CY2023Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
654000
CY2024Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
5081000
CY2023Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
5615000
CY2024Q3 us-gaap Inventory Net
InventoryNet
11892000
CY2023Q4 us-gaap Inventory Net
InventoryNet
10983000
CY2024Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5860000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4551000
CY2024Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3229000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2788000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2631000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1763000
CY2024Q3 us-gaap Depreciation
Depreciation
169000
CY2023Q3 us-gaap Depreciation
Depreciation
137000
us-gaap Depreciation
Depreciation
441000
us-gaap Depreciation
Depreciation
393000
CY2024Q3 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
2982000
CY2023Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
3335000
CY2024Q3 cvrx Accrued Paid Time Off
AccruedPaidTimeOff
931000
CY2023Q4 cvrx Accrued Paid Time Off
AccruedPaidTimeOff
770000
CY2024Q3 us-gaap Pension And Other Postretirement And Postemployment Benefit Plans Liabilities Current
PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesCurrent
876000
CY2024Q3 cvrx Accrued Liabilities Customer Rebate Current
AccruedLiabilitiesCustomerRebateCurrent
633000
CY2023Q4 cvrx Accrued Liabilities Customer Rebate Current
AccruedLiabilitiesCustomerRebateCurrent
411000
CY2024Q3 us-gaap Interest Payable Current
InterestPayableCurrent
276000
CY2023Q4 us-gaap Interest Payable Current
InterestPayableCurrent
220000
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
275000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
231000
CY2024Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
274000
CY2024Q3 cvrx Clinical Trial And Other Professional Fees
ClinicalTrialAndOtherProfessionalFees
205000
CY2023Q4 cvrx Clinical Trial And Other Professional Fees
ClinicalTrialAndOtherProfessionalFees
277000
CY2024Q3 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
167000
CY2023Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
125000
CY2024Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1052000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
611000
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7671000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5980000
CY2024Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
33333000
CY2024Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
16667000
CY2024Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
50000000
CY2024Q3 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
786000
CY2024Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
49214000
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1144000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1349000
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
275000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
231000
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
951000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1160000
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
1226000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
1391000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
86000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
350000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
362000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
374000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
223000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1395000
CY2024Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
169000
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
1226000
CY2024Q3 us-gaap Lessee Operating Lease Remaining Lease Term
LesseeOperatingLeaseRemainingLeaseTerm
P3Y10M24D
CY2024Q3 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.067
us-gaap Operating Lease Payments
OperatingLeasePayments
400000
us-gaap Operating Lease Payments
OperatingLeasePayments
300000
CY2024Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
103349
CY2024Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
12.92
CY2023Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
716131
CY2023Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
2.39
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4488845
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.77
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
97266000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
3170198
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
12.75
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
1514153
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
9.57
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
298513
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
5.39
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5846377
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
11.66
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
7857000
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2947395
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
8.90
CY2024Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
6927000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y10M24D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y2M12D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2680000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1532000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
16365000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4713000
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2680000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1532000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
16365000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4713000
CY2024Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
24100000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y9M18D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Incremental Compensation Cost
ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
8400000
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
47000
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
40000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
126000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
108000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-13099000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-9011000
us-gaap Net Income Loss
NetIncomeLoss
-49314000
us-gaap Net Income Loss
NetIncomeLoss
-32036000
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
22783337
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20801350
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21884588
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20730024
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.57
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.43
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.25
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.55
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5949726
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5180227
CY2024Q2 us-gaap Contractual Obligation
ContractualObligation
0
CY2023Q4 us-gaap Contractual Obligation
ContractualObligation
0
CY2024Q3 cvrx Defined Contribution Plan Employer Match Amount
DefinedContributionPlanEmployerMatchAmount
300000
CY2023Q3 cvrx Defined Contribution Plan Employer Match Amount
DefinedContributionPlanEmployerMatchAmount
0
cvrx Defined Contribution Plan Employer Match Amount
DefinedContributionPlanEmployerMatchAmount
900000
cvrx Defined Contribution Plan Employer Match Amount
DefinedContributionPlanEmployerMatchAmount
0
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
13373000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
10511000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
35950000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
27990000
ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001558370-24-014078-index-headers.html Edgar Link pending
0001558370-24-014078-index.html Edgar Link pending
0001558370-24-014078.txt Edgar Link pending
0001558370-24-014078-xbrl.zip Edgar Link pending
cvrx-20240930.xsd Edgar Link pending
cvrx-20240930x10q.htm Edgar Link pending
cvrx-20240930xex31d1.htm Edgar Link pending
cvrx-20240930xex31d2.htm Edgar Link pending
cvrx-20240930xex32d1.htm Edgar Link pending
cvrx-20240930xex32d2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
cvrx-20240930x10q_htm.xml Edgar Link completed
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
cvrx-20240930_def.xml Edgar Link unprocessable
cvrx-20240930_cal.xml Edgar Link unprocessable
cvrx-20240930_pre.xml Edgar Link unprocessable
cvrx-20240930_lab.xml Edgar Link unprocessable